Virology & Mycology Infectious Diseases
 
Untitled Document
   Publications A-Z
A
»Accounting & Marketing
» Addiction Research & Therapy
»Advances in Automobile Engineering
»Advances in Pharmacoepidemiology & Drug Safety
»Advances in Robotics & Automation
»Aeronautics & Aerospace Engineering
»Agrotechnology
»AIDS & Clinical Research
»Allergy & Therapy
»Air & Water borne Diseases
»Alzheimers Disease & Parkinsonism
»Analytical & Bioanalytical Techniques
»Anaplastology
»Anatomy & Physiology
»Andrology-Open Access
»Anesthesia & Clinical Research
»Antivirals & Antiretrovirals
»Applied & Computational Mathematics
»Applied Mechanical Engineering
»Aquaculture Research & Development
»Architectural Engineering Technology
»Arthritis
»Astrophysics & Aerospace technology
»Autacoids
»Autism-Open Access
  
B
»Bacteriology & Parasitology
»Bioanalysis & Biomedicine
»Biochemistry and Analytical Biochemistry
»Biochemistry & Pharmacology: Open Access
»Biochips & Tissue Chips
»Bioenergetics: Open Access
»Bioengineering & Biomedical Science
»Bioequivalence & Bioavailability
»Biofertilizers & Biopesticides
»Biometrics & Biostatistics
»Biomolecules
»Biochemistry & Physiology: Open Access
»Bioprocessing & Biotechniques
»Bioremediation & Biodegradation
»Biosafety
»Biosensors & Bioelectronics
»Biotechnology & Biomaterials
»Bioterrorism & Biodefense
»Blood Disorders & Transfusion
»Blood & Lymph
»Brain Disorders & Therapy
»Briefing in Intellectual Property Rights
»Business and Financial Affairs
  
C
»Cancer Science & Therapy
»Carcinogenesis & Mutagenesis
»Cell and Developmental Biology
»Cell Science & Therapy
»Chemical Engineering & Process Technology
»Chemotherapy: Open Access
»Chromatography & Separation Techniques
»Civil & Environmental Engineering
»Civil & Legal Sciences
»Clinical & Cellular Immunology
»Clinical Case Reports
»Clinical & Experimental Cardiology
»Clinical & Experimental Dermatology Research
»Clinical & Experimental Ophthalmology
»Clinical & Experimental Pathology
»Clinical & Experimental Pharmacology
»Clinical Pharmacology & Biopharmaceutics
»Clinical Research & Bioethics
»Clinical Toxicology
»Clinical Trials
»Cloning & Transgenesis
»Communicable & Noncommunicable Diseases
»Community Medicine & Health Education
»Computer Science & Systems Biology
»Cytology & Histology
D
»Data Mining in Genomics & Proteomics
»Defense Management
»Dentistry
»Depression and Anxiety
»Diabetes & Metabolism
»Drug Designing
»Drug Metabolism & Toxicology
  
E
»Earth Science & Climatic Change
»Ecosystem & Ecography
»Endocrinology & Metabolic Syndrome
»Entomology, Ornithology & Herpetology
»Environmental & Analytical Toxicology
»Epidemiology: Open Access
»Emergency Medicine: Open Access
»Ergonomics
»Electrical & Electronics
»Enzyme Engineering
»Entrepreneurship & Organization Management
  
F
»Fermentation Technology
»Fertilization : In Vitro
»Food Processing & Technology
»Forensic Research
»Forest Research: Open Access
»Fungal Genomics & Biology
  
G
»Gastrointestinal & Digestive System
»Genetic Syndromes & Gene Therapy
»Glycobiology
»Glycomics & Lipidomics
»Gynecology& Obstetrics
»Geography & Natural Disasters
»Geology & Geosciences
»Geophysics & Remote Sensing
»Gerontology & Geriatric Research
  
H
»Hair : Therapy & Transplantation
»Health & Medical Informatics
»Hereditary Genetics
»Homeopathy & Ayurvedic Medicine
»Hotel & Business Management
»Human Genetics & Embryology
»Hydrology: Current Research
»Hypertension- Open Access
  
I
»Industrial Engineering & Management
»Irrigation and Drainage Systems Engineering
»Information Technology & Software
Engineering
»Internal Medicine
  
L
»Liver
  
M
»Marine Science: Research & Development
»Mass Communication & Journalism
»Material Sciences & Engineering
»Medicinal Chemistry
»Medical Advancements in Genetic Engineering
»Medicinal & Aromatic Plants
»Medical Diagnostic Methods
»Medical Microbiology & Diagnosis
»Medical & Surgical Urology
»Membrane Science & Technology
»Metabolic Syndrome
»Metabolomics:Open Access
»Microbial & Biochemical Technology
»Molecular Biology
»Molecular Biomarkers & Diagnosis
»Molecular Imaging & Dynamics
»Mycobacterial Diseases
N
»Nanomedicine & Biotherapeutic Discovery
»Nanomedicine & Nanotechnology
»Neonatal Biology
»Nephrology & Therapeutics
»Neurology & Neurophysiology
»Novel Physiotherapies
»Nuclear Energy & Power Generation
Technologies
»Nuclear Medicine & Radiation Therapy
»Nutrition & Food Sciences
»Nutritional Disorders & Therapy
»Nursing & Care
  
O
»Obesity & Weight loss Therapy
»Outlook on Developing Drugs: Open Access
»Organ Biology
»Organic Chemistry: Current Research
»Orthopedic & Muscular System: Current Research
»Otolaryngology
  
P
»Pain & Relief
»Palliative Care & Medicine
»Pancreatic Disorders & Therapy
»Pediatrics & Therapeutics
»Petroleum & Environmental Biotechnology
»Pharmaceutica Analytica Acta
»Pharmaceutical Regulatory Affairs: Open Access
»Pharmaceutics & Drug Delivery Research
»Pharmacogenomics & Pharmacoproteomics
»Physical Chemistry & Biophysics
»Plant Pathology & Microbiology
»Powder Metallurgy & Mining
»Primatology
»Primary Health Care: Open Access
»Proteomics & Bioinformatics
»Psychology & Psychotherapy
»Pulmonary & Respiratory Medicine
  
R
»Radiology: Open Access
»rDNA Technology
»Reproductive System & Sexual Disorders
»Rheumatology: Current Research
  
S
» Single Cell Genomics & Proteomics
»Sleep Disorders & Therapy
»Social & Economical Issues of Biotechnology
»Socialomics
»Sports Medicine & Doping Studies
»Spine
»Stem Cell Research & Therapy
»Steroids & Hormonal Science
»Stock & Forex Trading
»Surgery: Current Research
  
T
»Telecommunications System & Management
»Textile Science & Engineering
»Thermodynamics & Catalysis
»Thyroid Disorders & Therapy
»Tissue Science & Engineering
»Translational Medicine
»Transplantation Technologies & Research
»Trauma & Treatment
»Tourism & Hospitality
  
V
»Vaccines & Vaccination
»Veterinary Science & Technology
»Virology & Mycology
»Vitamins & Trace Elements
  
W
»Women's Health Care
  
Y
»Yoga & Physical Therapy
 
   Browse by Subjects
Clinical
»Clinical & Experimental Pharmacology
»Forensic Research
»Cell Science & Therapy
»Stem Cell Research & Therapy
»Cancer Science & Therapy
»Carcinogenesis & Mutagenesis
»Cytology & Histology
»AIDS & Clinical Research
»Anesthesia & Clinical Research
»Transplantation Technologies & Research
»Clinical Research & Bioethics
»Clinical & Cellular Immunology
»Clinical & Experimental Cardiology
»Clinical & Experimental Dermatology Research
»Clinical & Experimental Ophthalmology
»Neurology & Neurophysiology
»Clinical & Experimental Pathology
»Pulmonary & Respiratory Medicine
»Clinical Toxicology
  
Pharmaceutical Sciences
»Vaccines & Vaccination
»Antivirals & Antiretrovirals
»Bioanalysis & Biomedicine
»Drug Metabolism & Toxicology
»Bioequivalence & Bioavailability
»Pharmaceutica Analytica Acta
»Pharmaceutics & Drug Delivery Research
»Clinical Pharmacology & Biopharmaceutics
»Outlook on Developing Drugs: Open Access
»Pharmacoepidemiology & Drug Safety
»Pharmaceutical Regulatory Affairs: Open Access
  
Chemistry
»Thermodynamics & Catalysis
»Physical Chemistry & Biophysics
»Organic Chemistry
»Chromatography & Separation Techniques
»Analytical & Bioanalytical Techniques
»Medicinal Chemistry
  
Environmental
»Earth Science & Climatic Change
»Environmental & Analytical Toxicology
»Aquaculture Research & Development
»Hydrology: Current Research
»Petroleum & Environmental Biotechnology
»Ecosystem & Ecography
  
Omics
»Pharmacogenomics & Pharmacoproteomics
»Data Mining in Genomics & Proteomics
»Proteomics & Bioinformatics
»Computer Science & Systems Biology
»Health & Medical Informatics
»Glycomics & Lipidomics
»Metabolomics:Open Access
  
Life Sciences
»Agrotechnology
»Marine Science: Research & Development
»Veterinary Science & Technology
»Plant Pathology & Microbiology
»Nutrition & Food Sciences
»Bioremediation & Biodegradation
»Biometrics & Biostatistics
»Bioengineering & Biomedical Science
»Microbial & Biochemical Technology
»Bioterrorism & Biodefense
»Biofertilizers & Biopesticides
»Social & Economical Issues of Biotechnology
»Biosensors & Bioelectronics
»Nanomedicine & Biotherapeutic Discovery
»Biochips & Tissue Chips
»Molecular Imaging & Dynamics
»Yoga & Physical Therapyy
»Tissue Science & Engineering
»Biotechnology & Biomaterials
»Biochemistry and Analytical Biochemistry
»Nanomedicine & Nanotechnology
»Membrane Science & Technology
»Bacteriology & Parasitology
»Enzyme Engineering
»rDNA Technology
»Cell and Developmental Biology
»Fermentation Technology
»Chemotherapy
»Biochemistry & Physiology
»Biomolecules
»Biochemistry & Physiology: Open Access
»Biochemical Pharmacology
»Bioenergetics
»Forest Research
»Fungal Genomics & Biology
»Medical Advancements in Genetic Engineering
»Biosafety
»Medicinal & Aromatic Plants
» Single Cell Genomics & Proteomics
»Vitamins & Trace Elements
»Women's Health Care
»Primatology
  
Engineering
»Advances in Automobile Engineering
»Advances in Robotics & Automation
»Aeronautics & Aerospace Engineering
»Applied Mechanical Engineering
»Architectural Engineering Technology
»Bioprocessing & Biotechniques
»Chemical Engineering & Process Technology
»Civil & Environmental Engineering
»Electrical & Electronics
»Food Processing & Technology
»Geology and Geosciences
»Geophysics & Remote sensing
»Industrial Engineering & Management
»Information Technology & Software
Engineering
»Irrigation and Drainage Systems Engineering
»Material Sciences& Engineering
»Powder Metallurgy & Mining
»Telecommunications System & Management
»Textile Science & Engineering
  
Medical Sciences
»Genetic Syndromes & Gene Therapy
»Steroids & Hormonal Science
»Virology & Mycology
»Communicable & Noncommunicable Diseases
»Molecular Biomarkers & Diagnosis
»Psychology & Psychotherapy
»Nuclear Medicine & Radiation Therapy
»Alzheimers Disease & Parkinsonism
»Dentistry
»Pediatrics & Therapeutics
»Rheumatology: Current Research
»Hereditary Genetics
»Reproductive System & Sexual Disorders
»Addiction Research & Therapy
»Allergy & Therapy
»Diabetes & Metabolism
»Blood Disorders & Transfusion
»Endocrinology & Metabolic Syndrome
»Nutritional Disorders & Therapy
»Medical Microbiology & Diagnosis
»Human Genetics & Embryology
»Gastrointestinal & Digestive System
»Otolaryngology
»Anatomy & Physiology
»Autacoids
»Sports Medicine & Doping Studies
»Nephrology & Therapeutics
»Community Medicine & Health Education
»Translational Medicine
»Entomology, Ornithology & Herpetology
»Orthopedic & Muscular System
»Epidemiology: Open Access
»Gynecology& Obstetrics
»Mycobacterial Diseases
»Anaplastology
»Surgery: Current Research
»Radiology: Current Research
»Internal Medicine
»Blood & Lymph
»Emergency Medicine
»Fertilization : In Vitro
»Palliative Care & Medicine
»Glycobiology
»Ergonomics
»Liver
»Neonatal Biology
»Medical Diagnostic Methods
»Hair: Therapy & Transplantation
»gerontology & Geriatrics Research
»Andrology
»Clinical Case Reports
»Spine
»Pain & Relief
»Depression and Anxiety
»Obesity & Weight loss Therapy
»Sleep Disorders & Therapy
»Nursing & Care
»Trauma & Treatment
»Primary Health Care: Open Access
»Clinical Trials
»Homeopathy & Ayurvedic Medicine
»Brain Disorders & Therapy
»Pancreatic Disorders & Therapy
»Metabolic Syndrome
»Novel Physiotherapies
»Thyroid Disorders & Therapy
»Air & Water borne Diseases
»Drug Designing
»Molecular Biology
»Cloning & Transgenesis
»Hypertension-Open Access
»Organ Biology
»Arthritis
 
Management
»Accounting & Marketing
»Business and Financial Affairs
»Civil & Legal Sciences
»Defense Management
»Entrepreneurship& Organization Management
»Hotel & Business Management
»Industrial Engineering & Management
»Mass Communication & Journalism
»Stock & Forex Trading
» Socialomics
»Tourism & Hospitality
 
   Conferences
Upcoming Conferences
»International Conference and Exhibition on Metabolomics & Systems Biology 20-22 February 2012 San Francisco, USA.
»2nd World Congress on Pharmaceutics & Novel Drug Delivery Systems 20-22 February 2012 San Francisco, USA.
»International Conference and Exhibition on Biometrics & Biostatistics 5-7 March 2012 Omaha, USA.
»2nd World Congress on Clinical & Experimental Dermatology 5-7 March 2012 Omaha, USA
»2nd World Congress on Clinical & Experimental Cardiology 5-7 March 2012 Omaha, USA.
» 2nd World Congress on Clinical & Experimental Ophthalmology 5-7 March 2012 Omaha, USA.
»International Conference & Exhibition on Nanotechnology and Nanomedicine 12-14 March 2012 Omaha, USA.
»World Congress on Gastroenterology and Urology 12-14 March 2012 Omaha, USA
»3rd World Congress on Bioavailability & Bioequivalence: Pharmaceutical R & D Summit 26-28 March 2012 Marriott Hotel, Hyderabad, India.
» International Conference and Exhibition on Neurology &Therapeutics 14-16 May 2012 Renaissance Las Vegas Hotel, Las Vegas, Nevada, USA.
»International Conference and Exhibition on Biosensors & Bioelectronics14-16 May 2012 Las Vegas, USA.
»3rd world Congress on Biomarkers & Clinical Research 2-4 July 2012 Las Vegas, USA.
»2nd world Congress on Proteomics & Bioinformatics 2-4 July 2012 Las Vegas, USA.
»International Conference and Exhibition on Orthopedics 13-15 August 2012 Chicago, USA.
»International Conference and Exhibition on Rheumatology and Therapeutics 14-15 August 2012 Chicago, USA.
»International Conference and Exhibition on Addiction Research & Therapy 20-22 August 2012 Las Vegas, USA.
»2nd World Congress on Virology 20-22 August 2012 Las Vegas, USA.
»International Conference and Exhibition on Nephrology and Therapeutics 20-22 August 2012 Hilton Chicago/Northbrook Chicago, USA.
»2nd World Congress on Vaccines & Vaccination 20-22 August 2012 at Chicago, USA.
»World Congress on Earth Science & Climate Change 21-22 August 2012 Chicago, USA.
»International Conference and Exhibition on pathology 27-29 August 2012 Philadelphia, USA.
»International Conference on Pulmonary & Respiratory Medicine 27-29 August 2012 Philadelphia, USA.
»International Conference and Exhibition on Nutritional Science & Therapy-2012 27-29 August 2012 Philadelphia, USA.
»International Conference on Central Nervous System 5-7 September 2012 Double by Hilton Philadephia, USA.
»International Conference on Occupational Health and Safety Summit 5-7 September 2012 Philadelphia, USA.
»International Conference on Hydrology and Groundwater Expo 10-12 September 2012 Hilton San Antonio Airport, USA.
»2nd World Congress on Cancer Science & Therapy 10-12 September 2012 San Antonio, USA.
»World Congress and Expo on Biowaivers and Biosimilars 10-12 September 2012 San Antonio, TX, USA.
»3rd World Congress on Biotechnology 13-15 September 2012 HICC, Hyderabad, India.
»International Conference on Biodiversity & Sustainable Energy Development 14-15 September 2012 Hyderabad, India.
»World Toxicology Summit & Expo-2012 17-19 September 2012 San Antonio Texas, USA.
»International Conference and Exhibition on Translational medicine-2012, 24-26 September 2012 Chicago USA.
»3rd World Congress on Diabetes & Metabolism which is to be held on 24-26 September 2012 Marriott Convention Center, Hyderabad, India.
»International Conference on Tissue Science and Engineering 1-3 October 2012 San Francisco, USA.
»International conference and Exhibition on Pharmacovigilance and Clinical Trials 1-3 October 2012 San Francisco, USA.
»Omics International Integrative Biology Summit 2012 1-3 October 2012 San Francisco, USA.
»International Conference & Exhibition on Emerging Cell Therapies 1-3 October 2012 San Francisco, USA.
»World Congress on Forensic Research & Technology 15-17 October, 2012 at DoubleTree by Hilton Chicago-North Shore, USA.
»International Conference and Exhibition on Otolaryngology 15-17 October 2012 Chicago, USA.
»International conference on Biothreats and Biodefense 15-17 October, 2012 at DoubleTree by Hilton Chicago-North Shore, USA.
»International Conference on Genetic Syndromes & GeneTherapy 22-24 October 2012 at DoubleTree by Hilton Chicago-North Shore, USA.
»International Conference on Clinical and Cellular Immunology 22-24 October 2012 Las Vegas, USA.
»International Conference and Expo on Material science and Engineering 22-24 October 2012 DoubleTree by Hilton Chicago-North Shore, USA.
» International Expo and Conference on Analytrix & HPLC 22-24 October 2012 Hilton Northbrook, Chicago, USA.
»International Conference and Exhibition on Computer Aided Drug Design & QSAR 29-31 October 2012, Chicago, USA.
»World Congress on Personalised Medicine & Molecular Diagnostics 12-14 November 2012 San Antonio, USA.
»2nd World Congress on Cell Science and Stem Cell Research 12-14 November 2012 Hilton San Antonio Airport, USA.
»International Conference on Clinical Microbiology & Microbial Genomics 12-14 November 2012 San Antonio, USA.
»World Congress on Regenerative and Functional Medicine 12-14 November 2012 at San Antonio, Texas, USA.
»Global Biofuels and Bioproducts Summit 19-21 November 2012 San Antonio, USA.
»International Conference and Exhibition on Probiotics-2012, 19-21 November 2012, Hilton San Antonio Airport, USA.
»International Conference and Exhibition on Food Processing and Technology 22-24 November 2012 Hyderabad, India.
»2nd World Congress on Pharmaceutical Regulatory Affairs 23-24 November 2012 HICC Hyderabad, India
»International Conference and Exhibition on Cosmetology & Cosmetics 23-24 November 2012 HICC Hyderabad, India.
»International Conference and Exhibition on Surgery & Transplantation 26-28 November 2012 Hilton San Antonio Airport, USA.
»International conference on Hair Transplantation and Trichology 26-28 November 2012 San Antonio, USA.
»World Congress on Novel approaches in Anaesthesia and Preoperative Care during 26-28 November 2012 San Antonio, USA.
»International Conference on Obesity and Weight Management 3-5 December 2012 Philadelphia, USA.
Previous Conferences Organized/Co-organized
»2nd world Congress on Analytical and Bioanalytical Techniques 16-17 December 2011San franscico, USA.
»2nd World Congress on Diabetes & Metabolism 6-8 December 2011 Philadelphia, USA.
»World Congress on Pediatrics & Gynecology 6-8 December 2011 Philadelphia, USA.
»International Conference and Exhibition on Cell Science & Stem Cell Research 29 Nov-1 Dec 2011 Philadelphia, USA.
»2nd World Congress on Biotechnology 29 Nov -1 Dec 2011 Philadelphia, USA.
»International Conference and Exhibition on Vaccines & Vaccination 22-24 November 2011 Philadelphia, USA.
»2nd World Congress on Biomarkers & Clinical Research 12-14 September 2011 Baltimore, USA.
»International Conference and Exhibition on Virology 5-7 September 2011 Baltimore, USA.
»International Conference and Exhibition on Pharmaceutical Regulatory Affairs 6-7 September 2011 Baltimore, USA.
»International Conference and Exhibition on Cancer Science & Therapy 15-17 August 2011 Las Vegas, USA.
»International Conference on Clinical Research: Dermatology, Ophthalmology and Cardiology 5-6 July 2011 San Francisco, USA.
»International Conference & Exhibition on Proteomics & Bioinformatics 6-8 June 2011 HICC, Hyderabad, India.
»International Conference & Exhibition on Pharmaceutical Biotechnology 6-8 June 2011 HICC, Hyderabad, India.
»2nd World Congress on Bioavailability & Bioequivalence: Pharmaceutical R & D Summit 6-8 June 2011 Las Vegas, USA.
»International Conference on Pharmaceutics & Novel Drug Delivery Systems 7-8 June Las Vegas, USA.
»World Congress on Biotechnology 21-23 March 2011 Hyderabad, India.
»International Conference on Diabetes and Metabolism 13-14 December 2010 Santa Clara, USA.
»International Conference on Biomarkers & Clinical Research 22-23 November 2010 Santa Clara, USA
»International Conference and Exhibition on Analytical and Bioanalytical Techniques: Pharmaceutical R & D Summit 01 - 03 November 2010 Hyderabad, India
»International Conference & Exhibition on Bioequivalence & Bioavailability 2010, Pharmaceutical R & D Summit March 01-03, 2010.
»Integrating Glycomics with other Omics in Cancer Detection and Diagnosis, January 19-20, 2010, Stanford University School of Medicine.
»3rd World Congress of Gene-2009, December 1-7, 2009.
»7th Annual World Congress of International Drug Discovery Science & Technology, October 22-25.
»2nd WSA-2009, July 18-20, 2009
»1st CCSB-2009, February 16-17, 2009
»2nd PRICPS-4th AOHUPO, June 22-26, 2008
»95th ISCA, January 5-8, 2008

Search :     Advanced Search 

Home   |   Join   |   Contact     

    
Journal Details
 
 
Research Article Open Access
A Bioequivalence Study Comparing Two Formulation of Emtricitabine Capsules
A.T.Bapuji*, M.Nagesh, D.Ramaraju, Syed Syedba, Ravi Kiran, S.Ravinder and D.Chandrapal reddy
Department of Clinical Pharmacology, APL research centre, (Aurobindo Pharma) Hyderabad
*Corresponding author: Dr. A.T.Bapuji
Clinical pharmacology department,
APL research centre, Survey no.313, Bachupally village,
Quthubullapur mandal, Hyderabad, 500072,
E-mail: bapuji@aurobindo.com
 
Received December 16, 2009; Accepted January 21, 2010; Published January 21, 2010
 
Citation: Bapuji AT, Nagesh M, Ramaraju D, Syedba S, Kiran R, et al. (2010) A Bioequivalence Study Comparing Two Formulation of Emtricitabine Capsules. J Bioequiv Availab 2: 011-014. doi:10.4172/jbb.1000023
 
Copyright: © 2010 Bapuji AT, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
 
Abstract
 
This investigation was carried out to evaluate the bioavailability of emtricitabine 200mg capsules (Test) of Aurobindo Pharma Ltd, India, relative to reference product, Emtriva 200mg capsules, manufactured by Gilead Sciences, Inc., USA. The bioavailability study was carried out on 36 healthy male volunteers who received a single dose of emtricitabine 200mg of the test (T) and the reference ( R ) products in the fasting state, in a randomized, balanced, 2-way cross-over design. After dosing, serial blood samples were collected for a period of 48 hours. Plasma obtained from blood was analyzed for emtricitabine by a sensitive and validated simultaneous liquid-chromatographic and mass-spectrometric (LC-MS/ MS) assay. The maximum plasma concentrations (Cmax), area under the plasma concentration-time curve up to the last measurable concentration (AUC0-t), and to infinity (AUC0-α) and the time to maximum concentration (tmax) were analyzed statistically. The parametric confidence intervals (90%) were calculated. It was found that the test/reference (T/R) ratios for the pharmacokinetic parameters (AUC0-t), (AUC0-α) and (Cmax) were well within the Bioequivalence acceptance range of 80 – 125% as per international regulatory guidelines. Therefore, the two formulations were considered to be bioequivalent.
 
Keywords
 
Emtricitabine; Bioequivalence-study pharmacokinetics statistics
 
Introduction
 
Emtricitabine (FTC; Emtriva), a potent doxycytidine nucleoside reverse transcritase inhibitor is used to treat human immunodeficiency virus (HIV) infection. In adults, FTC has demonstrated linear kinetics over a wide dose range and FTC 200mg once a day is the recommended therapeutic dose. Emtricitabine is consistently (4-10 times) more patent than lamivudine (3TC) in vitro against laboratory strains and primary clinical isolates of HIV (Schinazi et al., 1992; Schinazi et al., 1993; Tisdale et al., 1993). As a nucleoside reverse transcriptase inhibitor (NRTI), emtricitabine is readily anabolized by cellular enzymes in a step wise fashion to form its mono phosphate, diphosphate, and finally 5'-triphosphate (TP) form, the active intracellular moiety that inhibits HIV-1 reverse transcriptase (RT) and HBV DNA polymerase (Wilson et al., 1993; Furman et al., 1995; Davis et al., 1996).
 
Emtricitabine is rapidly and extensively absorbed followed oral administration, with peak plasma concentration occurring within 1.5 hr of dosing and with an oral bioavailability >90% (Wang et al., 2001; Gish et al., 2002). Emtricitabine disposition follows linear kinetics with small intersubject variability and plasma emtricitabine concentrations increased dose propotionally over a wide dose range (100-1200mg) (Wang et al., 1995). Emtricitabine does not appreciably bind to plasma proteins (<4%) and is primarily eliminated from plasma as unchanged drug in urine (about 65-70% of an oral dose), with a plasma elimination half-life of 8-10hr (Wang et al., 2001).
 
A new generic formulation has been developed having the same composition as innovator brand and the method of manufacture is wet granulation.
 
A single dose 200mg of emtricitabine has been evaluated in this study. The pharmacokinetics of emtricitabine were evaluated in 36 healthy male volunteers. The aim of this study was to determine the Bioequivalence and to compare the pharmacokinetics of two formulations (innovator vs. generic) of emtricitabine 200mg capsules.
 
Materials and Methods
 
Study design
 
This study was an open label, randomized, two-treatment, twosequence, two-period, cross-over, single-dose comparative oral bioavailablity study of emtricitabine 200mg capsules (Test) of Aurobindo Pharma Ltd., India and Emtriva 200mg capsules (Reference) of Gilead Sciences Inc., USA.
 
All study medications were kept in a pharmacy and temperature and humidity were monitored continuously. A SAS generated randomization code was used to ensure balanced permutation of the treatments. Both test and reference formulations were administered with 240 ml of water in one of their periods of crossover that was separated by a washout period of 8 days. The subjects were confined to the clinic through out the 24- hour postdose and returned for the 36 and 48-hour during each study period. During the trial, the subjects were to remain ambulatory or sealed upright for the first 4 hours after drug administration. During housing, post-dose meals were identical for both periods of the study. Lunch, dinner and snack were served at 4.0, 8.0 and 13.0 hours, respectively, after dosing. As per the FDA Guide lines, water was not permitted from 1 hour before dosing until 1 hour following dosing, but it was allowed at all other times.
 
The protocol and informed consent forms (ICFs) were reviewed and approved prior to study initiation by an independent Institutional Review Board (IRB). The IRB operates in accordance with the principles and requirements described in the US Code of Federal Regulations (21 CFR Part 56). All subjects read and signed the ICF prior to study initiation. This clinical trial was conducted in accordance with the Declaration of Helsinki, good Clinical Practice guidelines.
 
Subjects and treatments
 
The subjects were screened within 28 days prior to study enrolment. The screening procedure included medical histories and demographic data, including name, sex, age, race, body weight (kg), height (cm), and tobacco use. Healthy adult male volunteers were to fulfill all of the following inclusion criteria to be eligible for participation in the study. Males with a minimum age of 18 years and body mass index greater than or equal to 18.04 kg/m2 and less than or equal to 25.00 kg/m2. These criteria were used for the selection of healthy volunteers since they are associated with the lowest mortality rate in the population as per the Metropolitan Life Insurance Company. All subjects were subjected to a vital signs measurement, a 12-lead electrocardiogram (ECG), and laboratory tests to evaluate their hematologic, hepatic and renal functions, prior to study enrolment, the clinical investigator reviewed the screening data and performed the physical examinations. The subjects were not to consume any food and beverages containing xanthines or alcohol (48 hours before dosing and throughout the period of sample collection), grapefruit (72 hours before dosing and throughout the study), or vitamins (throughout the confinement period). Subjects were to be nonsmokers; medication (including herbal and over-the-counter products) was prohibited for the 14 days preeding the study and also during the study. On the evening prior to each dosing, all subjects were screened for cocaine, cannabinoids, benzodiazepines, Opioids, Amphetamines, barbiturates and alcohol. A total of 36 healthy adult male volunteers who had satisfied the above screening criteria were admitted to the study center in the evening before dosing (Day-1), then they were assigned to each treatment sequence as per the randomization scheme. All the subjects received doses of 200 mg emtricitabine capsules on the dosing day.
 
Adverse events were monitored throughout the study, until resolution or loss to follow-up. Adverse events were described in terms of severity, scriousness, outcome, action, frequency and relationship to treatments. The principal investigator or sub-investigator was on-site, within the proximity of the subject confinement area for first 6 hours after drug administration. Subjects were instructed to inform the study physician and/or nurses of any adverse events that occurred during the study.
 
Blood sample collection
 
Blood samples (1 x 6 ml) for emtricitabine analysis were collected in EDTA vacutainers at hour 0.00 (pre-dose) and at 0.25, 0.50, 0.75, 1.0, 1.25, 1.50, 1.75, 2.0, 2.25, 2.50, 3.0, 4.0, 6.0, 8.0, 10.0, 12.0, 16.0, 20.0, 24.0, 36.0 and 48.0 hours post dose. Immediately, blood samples were centrifuged under refrigeration and then plasma was separated and stored at –70°C ±10°C at the clinical unit of Trident Life sciences Ltd and then transferred to the bioanalytical facility of Trident life sciences Ltd under frozen condition and then samples were stored at –70°C or below until sample analysis.
 
Analytical Methods
 
Plasma concentrations of emtricitabine were assessed by a simultaneous method using high-performance liquid chromatography with mass spectrometry detection (LC-MS/MS). Method validation was performed according to the current international approach and the applicable regulations regarding bioanalytical method validation (FDA, 2001). An aliquot of human plasma containing the analyte and the internal standard was extracted using a solid-phase extraction (SPE). The internal standard for emtricitabine assay was lamivudine. 50μl of the internal standard working solution (lamivudine in 1:1 methanol: water solution) were added to 300 μl of each plasma sample. After vortexing the tubes, 100 μl of diluted Ortho phosphoric acid solution was added and the tubes were again vortexed. The mixture was transferred to preconditioned Oasis HLB (1CC/30mg) extraction cartridges. The analytes were eluted off from the extraction cartridge with 1 ml acetonitrile. Eluent was evaporated and reconstituted with the mobile phase (0.1%formic acid (pH 2.6): acetonitrile:Methanol (10:27:63 v/v)). The extracts were injected into the LC-MS/MS system equipped with AB/MDS Sciex API- 3000 mass spectrometer. Positive ions were monitored in the multiple reaction-monitoring (MRM) mode. The following ion transitions using analyst 1.4.2 were monitored 248.1/130.2 and 230.4/112.1 emtricitabine and internal standard respectively.
 
Linearity for emtricitabine was assessed by plotting area ratios versus standard concentrations and using a linear regression weighted 1/concentration 2. Analytical range for emtricitabine was 5.03 – 4008.47 ng/ml. Inter-and intrabatch precision and accuracy were assessed at low, medium and high QC concentration level. For emtricitabine interbatch precision (CV%) results were less than 4.3% and accuracy (%theoretical) results ranged between 98.7 and 102.1% Intrabatch precision (CV%) results were less than 5.9% and accuracy (%theoretical) results ranged between 98.6 and 103.7%.
 
Pharmacokinetics and statistical analysis
 
The following PK parameters were calculated using validated PK software (WinNonlinversion 5.0.1). The area under the curve from time zero to the last measurable concentration (AUC0-t) using the linear trapezoidal rule, the area under the curve extrapolated to infinity (AUC0-t + Clast /kel, where Clast is the last measurable plasma concentration), the maximum plasma concentration (Cmax), and the time to maximum plasma concentration (tmax), the terminal rate constant of elimination (kel) and terminal elimination half-life (t1/2). The ratio of AUC0-t - AUC0-α (AUC0-t/AUC0-α) as well as the extrapolated area of the curve (AUC0-α = (AUC0-α - AUC0-t)/ AUC0-α) were calculated as percentage. In addition, the oral clearance (Cl/F) was calculated as Dosc/AUC0-α. Concentration values below the LOQ of the assay for emtricitabine (5.03ng/ml) were set to zero. Analyses of variance (ANOVA) were performed on In-transformed AUC0-t, AUC0-α and Cmax parameters. The ANOVA model included sequence, subjects nested within sequence, period and drug formulation as factors according to regulatory guidance on Bioequivalence. A statistical analysis was performed using the SAS® GLM procedure (SAS® system for windows® release 9.1.3) Geometric least-square means (LSM) as well as ratio of LSM with corresponding 90% confidence intervals (CI’s) for the generic and innovator formulations were calculated. In addition, nonparametric methods were used to assess differences in median values of tmax between the two formulations and 90% CI’s were constructed.
 
Results
 
Demographics and safety results
 
36 male subjects representing the general population were enrolled in this study, but only 32 subjects completed the study and their demographics are as follows, mean age, height and weight were 26.81(19-40) years, 165.06(154-186) cm and 58.72 (50- 72) kg, respectively. The subjects’ mean BMI was 21.56 (18.04 – 25.00) kg/m2. 4 subjects withdrew from the study prior to receiving the formulation (1subject for test and 3 subjects for reference) due to absent for the participation in period 2 and positive for drugs of abuse. No deaths or serious adverse events occurred during conduct of this study. None of the subjects shown any adverse events except post study laboratory abnormalities.
 
Pharmacokinetics and statistics
 
Mean plasma concentration profiles of emtricitabine under linear over the 48-hour pharmacokinetic study are presented in Figure 1. Overall, mean plasma concentrations of emtricitabine peaked rapidly and then declined in a monoexponential manner, with most plasma concentration values falling below the LOQ of the assay at 48 hours postdose. Values below the LOQ were set to zero for pharmacokinetic analysis. A8-day washout period between treatments was sufficient since all predose concentration levels of emtricitabine were below the LOQ of the assay in Period 2. Mean plasma concentrations of emtricitabine following oral administration of these formulations were almost superimposable during the early absorption, distribution and elimination phases of the products Ratios of AUC0-t/AUC0-α for all the subjects found to be more than 80% indicating the blood samples collected adequately characterized the pharmacokinetic profile of the drug. In addition, a sample size of 32 subjects provided 100% power to detect a difference of at least 20% in Cmax, AUC0-t and AUC0-α between the two treatments.
 
fig
Figure 1: Linear mean plot of Emtricitabine 200 mg capsule concentration Vs time under fasting conditions
 
The statistical results of primary pharmacokinetic parameters of emtricitabine are presented in Table 1. The ANOVA probability values for the pharmacokinetic parameters Cmax, AUC0-t and AUC0-α are presented in Table 2.The Geometric mean ratios of test and references for Cmax, AUC0-t and AUC0-α were 99.37, 104.91 and 105.13% for emtricitabine and are presented in Table 3. The 90% CIs for emtricitabine were within 80.0-125.0%, suggesting the generic formulation developed by Aurobindo is bioequivalent with Emtriva of Gilead Sciences Inc., USA. The intra subject coefficient of variation for both untransformed and Lntranformed pharmacokinetic parameters Cmax, AUC0-t and AUC0-α are presented in Table 4.
 
Table 1: Summary Statistics of Emtricitabine. aMedian (range)
 
Table 2: ANOVA.
 
Table 3: 90% Confidence Intervals.
 
Table 4: Intra Subject CV%.
 
Discussion
 
The current investigation demonstrates both generic and innovator capsule formulations displayed similar rate and extent of bioavailability of emtricitabine. The Tmax for reference is found to be 1.25 hr and for reference it is 1.00 hr. The Tmax is comparable. The Cmax is found to be consistent both for test and reference indicating the attainment of body peak levels similarly. Cmax was found to be 17% inter subject variation for test preparation and 24.77% for reference preparation. However the mean data is very much comparable. For the AUC0-t parameter the results found to be similar and not much difference in inter subject variability and similarly for AUC0-α. The T1/2 values are also comparable and in the elimination phase there is no variation.
 
The statistical analysis was carried out for both untransformed and log transformed data. The data is showing statistical equivalence for the important pk parameters i.e. Cmax, AUC0-t and AUC0-α. The 90% confidence intervals are well within the limits and can be acceptable by any regulatory agency. A power of 100% was achieved for the PK parameters. The intra subject CV was found to be 14.60% for Cmax, 6.08% for AUC0-t and 6.12% for AUC0-α for log transformed data. Based on the results the generic is found to be bioequivalent and can be substituted for brand product.
 
Although the generic formulation does a significant cost reduction at this point of time the exact figures are not available.
 
The present investigation has been successfully conducted in 36 healthy male volunteers. During the clinical study there were no significant protocol/SOP deviations and adverse events were mild in nature. The subjects well tolerated the study medication. The biological samples were successfully analysed by LCMS/ MS. The quality control data is found to be consistent and precise. As a result, the generic capsule formulation of emtricitabine developed by Aurobindo Pharma Limited should be equally effective and safe as the innovator product of Emtriva manufactured by Gilead Sciences Inc., USA and is expected to produce considerable cost-savings in the AIDS population worldwide.
 
References
 
  1. Davis MG, Wilson JE, Van Draanen NA, Miller WH, Freeman GA, et al. (1996) DNA polymerase Activityof hepatitis B virus particles: Differential inhibition by L-enantiomers of nucleoside analogs. Anti-viral Res 30: 133- 145.  »  CrossRef  »  PubMed  »  Google Scholar

  2. FDA.Guidance for industry: bioanalytical method validation. U.S. (2001) Department of Health and human services. Food and drug admin-istration, Center for Drug Evaluation and Research: Rockville p1-22.

  3. Furman PA, Reardon JE, Painter GR (1995) The role of absolute configuration in the anti-HIV and anti-HBV activity of nucleoside analogs. Antiviral Chem Chemother 6: 345-355. »  CrossRef »  Google Scholar

  4. Gish RG, Leung NWY, Wright TL, Wang C, Corey L, et al. (2002) A dose ranging study of the pharmacokinetics, safety and preliminary antiviral activity of emtricitabine in adults with HBV infection. Antimicrob Agents Chemother 46: 1734-1740.  »  CrossRef »  Google Scholar

  5. Schinazi RF, McMillan A, Cannon D, Mathis R, Lloyd RM, et al. (1992) Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5- yl]cytosine. Antimicrob Agents Chemother 36: 2423-2431.  »  CrossRef  »  PubMed  »  Google Scholar

  6. Schinazi RF, Lloyd RM, Nguyen MH, Cannon cL, McMillan A, et al. (1993) Characterization of human immunodeficiency viruses resistant to oxathiolane- cytosine. Antimicrob Agents Chemother 37: 875- 881. »  CrossRef  »  PubMed  »  Google Scholar

  7. Tisdale M, Kemp SD, Parry NR, Larder BA (1993) Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3' thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci 90: 5653-5656. »  CrossRef  »  PubMed  »  Google Scholar

  8. Wang LH, Gardner P, Frick LW, Noblin JE, Blum MR (1995) Pharmacokinetics and safety of 524W91 following single oral administration of escalating doses in HIV-infected volunteer. Program and Abstracts of the 35th Interscience3 Conference on Antimicrobial Agents and Chemotherapy, San
    Francisco, CA p24. 

  9. Wang LH, Blum MR, Hui J, Hulett L, Chittick G (2001) Lack of significant pharmacokinetic interactions between emtricitabine (Coviracil) and other nucleoside antivirals in healthy volunteers, Program and Abstracts of the 41 st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL p18.

  10. Wilson JE, Martin JL, Borroto-Esodo K, Hopkins S, Painter G, et al. (1993) The 5'- triphosphates of the (-) and (+) enantiomers of cis-5-fluoro-1-[2- hydroxymethyl-1,3-xathiolane-5-yl]cytosine equally inhibit human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 37: 1720-1722. »  CrossRef  »  PubMed  »  Google Scholar

 
 
 
This Article
DOWNLOAD
» XML (39 kB)
» PDF (601 kB)
» Citation
   
CONTRIBUTE
» Write a Response
» Read other Responses
» Publishing with OPG
   
SHARE
» E-mail This Article
» Print This Article
» Rights and Permissions
   
Share
EXPLORE
Related Article at
» Pubmed
» DOAJ
» Scholar Google
 
 
 
 
Untitled Document
| More
OMICS Publishing Group: An Open Access Publisher
OMICS Publishing Group is the member of/publishing partner of/source content provider to
All Published content, except where otherwise noted, is licensed under a Creative Commons Attribution License.